Dune Medical Raised $12.3 Million for RF spectroscopy

9 July, 2017

Dune Medical is utilizing RF electrical fields to identify microscopic residual cancerous lesions at the area of tissue being examined

Share via Whatsapp
Dune Medical MarginProbe RF Spectroscopy

Dune Medical Devices from Caesarea, Israel, has developed  an innovative RF Spectroscopy technology to differentiate cancerous from healthy tissue based on electromagnetic properties. Its MarginProbe System is mostly used during breast cancer surgery, but is being explored for other applications and disease sites.

In August 2016, Dune celebrated receipt of three million euros awarded by a prestigious EU Horizon 2020 grant to support the continued development of its RF spectroscopy based biopsy system. Las week Dune Medical announced the closing of a $12.3 million dollar financing round  led by Canepa Healthcare, ATON Partners, and the Kraft Group.

“This financing round is a testament to the success of the revolutionary radiofrequency (RF) spectroscopy technology that created our first product, the MarginProbe,  said Dune Medical CEO Lori Chmura. “It is the basis for our surgical oncology platform which is quickly becoming the standard of care in cancer treatment.”

2,500 Positive Results

Since receiving FDA approval, the MarginProbe System has successfully demonstrated a consistent and significant reduction in re-excisions when women undergo breast conserving surgery after a diagnosis of early-stage breast cancer. To date, three large randomized controlled trials over 2,500 women who have undergone lumpectomy with MarginProbe shows a reduction in re-excision rates up to 79%. The impact of this reduction is very significant: Data indicates that without effective margin assessment 20-30% of women who undergo lumpectomy for breast cancer will undergo an additional surgical procedure to ensure negative margins.

Dune Medical’s technology is utilizing RF electrical fields, similar to the frequency range of FM radio, to identify microscopic residual cancerous lesions at the area of tissue being examined. The technology is based on two main principles: Reflection of electromagnetic fields depends on the underlying electrical properties of the tissue they interact with, and that the electrical properties of cancerous tissue are different from those of normal tissue

Tissue is a complex organ, with various components of the tissue contributing to its electrical properties. Any change in a cell’s physiological state will be reflected in its electrical response. Dune’s technology can capture these changes and provide immediate feedback to physicians, who need to decide if tissue is malignant or benign.

Posted in: Medical , News